搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
16 天
“被忽视的英雄”酪氨酸!Sci. Adv|饮食中非必需氨基酸Tyr对寿命的 ...
必需氨基酸(EAAs),如蛋氨酸(Met),在调控寿命方面发挥着重要作用,Met限制已被证实可以显著延长多种生物的寿命。相比之下,非必需氨基酸(NEAAs)的作用往往被忽视。相关研究发现,酪氨酸(Tyr)等NEAAs在调节寿命、代谢、繁殖和进食行为中 ...
生物谷
5 天
Nature:蛋白质测序技术突破:PASTOR单分子水平精准解读蛋白质突变和 ...
研究通过设计特殊的蛋白质结构块(每块59个氨基酸)并引入单个氨基酸突变,使用双酪氨酸标记(tyrosine mutation)来分割电流信号,进而实现对氨基酸序列的识别和翻译后修饰的探测。 纳米孔技术结合解折酶ClpX读取蛋白质的过程(Credit: Nature) 蛋白质通过纳米孔的 ...
3 小时
Breaking barriers. How nanozymes are revamping collagen-based biomaterials
A CSIR-CLRI study has showed that nanozymes can ensure collagen’s integrity and enhance resistance to enzymatic degradation ...
1 天
on MSN
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
5 天
ESMO中国之声丨李健教授团队报道INTRIGUE中国桥接研究的长期随访更新
本次ESMO大会进一步更新报道了中国桥接研究的数据。这项Ⅱ期研究招募了对伊马替尼治疗失败或不耐受的GIST成年患者,随机(1:1)接受瑞派替尼150 mg每日一次(QD)或舒尼替尼50 mg ...
1 天
on MSN
Researchers identify novel endocytic recycling mechanism with 'kiss-and-run' membrane fusion
Endocytosis and recycling control the uptake and retrieval of various materials in eukaryotic cells. Mammalian cells have ...
12 小时
on MSN
5 questions about Chronic Myeloid Leukemia answered
Chronic Myeloid Leukemia (CML) affects millions worldwide, including a rising number in India. Effective management involves ...
19 天
CELL DISCOV|清华生命学院团队联合北大肿瘤医院团队攻关BTK-PROTAC降解 ...
2024年8月6日,清华大学生命学院/免疫所/生命中心刘万里团队,联合清华大学药学院饶燏团队和北京大学肿瘤医院丁宁团队携手在《细胞发现》(Cell ...
BioWorld
2 天
MS Aubagio tableau: Sanofi talks tolebrutinib, Immunic the pick?
The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...
2 天
FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With ...
Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...
4 天
Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation
Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...
Medscape
1 天
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈